Masterhead

Thank you for visiting windsor.gate2bay.com. Fill in the form below:

Name/Corp.:

E-mail:

Subject:

Message:

Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand

Published Tuesday March 14

LTI-01 addresses unmet needs in a $600+ mill. global market.

Intended to replace costly surgery and ineffective off-label treatments of fibrosis, the drug can provide safer and more cost-effective therapeutic options for CPE/empyema patients and healthcare providers worldwide.

Future Therapeutic Options for Treating Fibrosis

About Lung Therapeutics, Incorporated

Article length: About 560 words.
Tags: Windsor
Read more at Medindia

google-468x60a

Share This Post

DeliciousDiggGoogleStumbleuponRedditTechnoratiYahooBloggerMyspaceRSS

selfad-writeart-b